KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 133 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $127,000 | -10.6% | 40,000 | 0.0% | 0.02% | -15.4% |
| Q2 2018 | $142,000 | -23.7% | 40,000 | 0.0% | 0.03% | -27.8% |
| Q4 2017 | $186,000 | -36.3% | 40,000 | 0.0% | 0.04% | -41.9% |
| Q3 2017 | $292,000 | +1.0% | 40,000 | 0.0% | 0.06% | -6.1% |
| Q2 2017 | $289,000 | +24.6% | 40,000 | 0.0% | 0.07% | +22.2% |
| Q1 2017 | $232,000 | – | 40,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management I, LLC | 1,312,006 | $22,357,000 | 15.70% |
| VHCP Management, LLC | 1,000,273 | $17,045,000 | 8.86% |
| HARVEY CAPITAL MANAGEMENT INC | 915,800 | $15,605,000 | 6.22% |
| Baupost Group | 6,310,850 | $107,537,000 | 2.60% |
| SECTORAL ASSET MANAGEMENT INC | 3,537,590 | $60,281,000 | 2.48% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 587,504 | $10,011,000 | 2.31% |
| Knoll Capital Management, LLC | 200,000 | $3,408,000 | 1.76% |
| Camber Capital Management LP | 1,250,000 | $21,300,000 | 1.67% |
| NORTHPOINTE CAPITAL LLC | 877,875 | $14,958,000 | 1.52% |
| DAFNA Capital Management LLC | 100,000 | $1,704,000 | 1.46% |